Article Text

FRI0347 Tubastatin A, A Selective Histone Deacetylase-6 Inhibitor, Suppresses Synovial Inflammation and Joint Destruction in A Collagen Antibody-Induced Arthritis Mouse Model
  1. J. Lee1,
  2. H. Jeong1,
  3. I.Y. Kim1,
  4. J. Hwang1,
  5. H. Kim1,
  6. C.H. Jeon2,
  7. H.-S. Cha1,
  8. E.-M. Koh1
  1. 1Samsung Medical Center
  2. 2SoonChunHyang Hospital, Seoul, Korea, Republic Of


Background Histone deacetylases (HDAC) play a key role in regulating gene expression by deacetylasing histones, and HDAC inhibitors induce various cellular effects, including apoptosis, cell cycle arrest and inhibition of angiogenesis. Tubastatin A is a potent and selective HDAC-6 inhibitor and its anti-rheumatic effect has not been determined.

Objectives This study was undertaken to investigate the effect of Tubastatin A on synovial inflammation and joint destruction in collagen antibody-induced arthritis (CAIA) mouse model.

Methods CAIA mice were given daily intraperitoneal injections of various concentration of Tubastatin A (0, 10, 50, 100mg/kg, n=6 each). Clinical score, paw thickness, and body weight were measured for 14 days. On day 15, mice were sacrificed and the expression of TNF-α, IL-1, IL-6 from the serum was analyzed using ELISA. Hind foot was examined histologically and synovitis was scored by 2 independent pathologists. Micro CT of the joints was performed and joint destruction was quantified. Cell viability and the expression of inflammatory cytokines in human fibroblast-like synoviocytes (FLS) after incubation with various doses of Tubastatin A (0, 0.75, 1.5, 3μM) were measured using MTT assay and ELISA, respectively.

Results In the Tubastatin A-treated group, clinical arthritis was attenuated and paw thickness was lower and this effect was statistically significant in the Tubastatin 100mg/kg group compared to control (p<0.01). All mice lost a small amount of weight but the difference was not statistically significant between groups. In the Tubastatin A 100mg/kg group, the histological severity of synovial inflammation as measured by synovial hypertrophy, density of resident cells, and inflammatory cell infiltrates was significantly lower compared with control (p<0.01, each). In addition, micro CT showed that joint destructions as measured by bone volume/tissue volume and bone surface area/bone volume were significantly less in the Tubastatin 100mg/kg group compared with control (p<0.05). Among pro-inflammatory cytokines, expression of IL-6 in the serum was significantly lower in the Tubastatin A 50mg/kg group compared with control (p<0.05). The expression of IL-6 from human FLS after incubation with Tubastatin A decreased in a dose-dependent manner without affecting the cell viability.

Conclusions Our data demonstrated that Tubastatin A, a selective HDAC6 inhibitor, ameliorates synovial inflammation and protects against joint destruction in CAIA mice, and reduced expression of IL-6. Our data suggest that Tubastatin A warrant further investigation as a potential therapeutic agent in rheumatoid arthritis.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3467

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.